Nuplazid's Black Box: Warning May Depend On Antipsychotic Classification
Advisory committee questions whether an antipsychotic drug class boxed warning should go in the Nuplazid label if it is approved; some debate whether the product is part of that class.
You may also be interested in...
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.